drugset / Trial / NCT02932475

Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)

NCT02932475 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Purpose: The objective of this proposal is to study the safety and efficacy of metformin added to insulin for treatment of type 2 diabetes mellitus (T2DM) among pregnant women. Participants: 950 pregnant women with type 2 diabetes complicating pregnancy from 10 U.S. clinical centers Procedures (methods): Pregnant women with T2DM between 10 weeks and 22 weeks 6 days and a singleton fetus will be randomized to double-blinded insulin/placebo versus insulin/metformin. Primary outcome is composite adverse neonatal outcome (clinically relevant hypoglycemia, birth trauma, hyperbilirubinemia, stillbirth/neonatal death). Study visits monthly at clinical visits; blood draw at 24-30 weeks, newborn anthropometric measurements at less than 72 hours of life. Maternal and infant outcomes will be chart abstracted.

Timeline

Start
2017-05-25
Primary completion
2022-06-15
Completion
2022-06-15

Outcome

Outcome not reported

Stopped: “Recommendation by the DSMB that the study be stopped for futility”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule 1000 mg Oral